|
International Journal of Biomedical Science
1(1) 72-75
|
|
|
© 2005 Master Publishing Group
|
|
Original Article
[FullText]
[PDF] |
|
|
Seroepidemiological Study On SARS-CoV IgG Antibodies Of Different Populations From Several Areas. |
|
SHI Yu-ling1, LI Lin-hai1,
CHU Xin-wei2,
CHEN Qing2, WANG Yun-long3,
MA Qing-jun4, CAO Cheng4,
YU Shou-yi2 |
1 Clinical Laboratory, Guangzhou General Hospital of PLA,
Guangzhou, 510515
2 Department of Epidemiology, First Military Medical
University, Guangzhou 510515, China
3 Center of Biotechnology and
Engineering of Henan Province, Zhengzhou,450000
4 Institute Biotechnology,
Academy of Military Medical Sciences, Beijing, 100850 |
|
severe acute respiratory syndrome; serum antibodies; ELISA; IFA |
|
|
Objective In order to investigate the clinical and epidemiological rules of
severe acute respiratory syndrome(SARS), rates and levels SARS coronavirus(
SARS-CoV) IgG antibodies of the patients and community populations from several
areas were detected . Methods Indirect immunofluorescent assay(IFA) and
double-antigen sandwich enzyme-linked immunosorbent assay (ELISA) were used to
detect the SARS coronavirus-specific IgG antibodies in sera of 1700, including
1453 general populations from Hongkong, Marco, Guangzhou and Peking and 257 SARS
patients from Guangzhou and Peking. The dynamics of the serum antibodies of SARS
patients were observed from 3 to 360 days after onset of symptoms. Results 90%
of 257 patient serum specimens after 20 days of disease onset showed positive
SARS-CoV IgG either using ELISA or IFA . 257 SARS patients, antibodies titers
increased steadily in early 4 to 6 months after onset of SARS. The titers of
most cases came to the peak in the 6th month. then antibodies titers declined
rapidly in some cases. However, all specimens still were positive for SARS-CoV
IgG in the 48th month . Conclusions This study suggest that few inapparent
infectious patients exist during SARS epidemic. Serum IgG antibodies has
diagnostic value for SARS in the late course of disease and the antibodies
present more than 48 months.
|
|
|